Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. reported 3 US-listed holdings worth $177.2 million in its 13F for the quarter ended 30 June 2026, filed 7 August 2026. Its largest: Parabilis Medicines Inc. Com (64.4%), Intellia Therapeutics Inc. (35.4%) and Adicet Bio Inc. (0.3%). Against the quarter before, it opened 2 positions, added to 0, trimmed 0 and sold out of 1.
The 3 largest of its 3 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +203.7% over the 6 quarters to 30 June 2026, against +27.4% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Opened 2
- Parabilis Medicines Inc. Com PBLS$114.0 million
- Adicet Bio Inc. ACET$522,819
Sold out of 1
- Adicet Bio Inc. ACET$412,080 last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Parabilis Medicines Inc. Com PBLS | 4.2M | $114.0 million | 64.35% | new |
| Intellia Therapeutics Inc. NTLA | 3.7M | $62.7 million | 35.35% | no change |
| Adicet Bio Inc. ACET | 60.5K | $522,819 | 0.30% | new |